You are here

  • Home
  • Archive
  • Volume 79, Issue 11
  • Lessons from tofacitinib in patients with cardiovascular risk factors: increased pulmonary embolism or isolated (thrombotic) pulmonary occlusion rates?

Share

Article menu

Download PDFPDF

Editorial
Lessons from tofacitinib in patients with cardiovascular risk factors: increased pulmonary embolism or isolated (thrombotic) pulmonary occlusion rates?
Free

Share this article

Click the icon of the social media platform on which you would like to share this article.

Twitter logo Facebook logo LinkedIn logo

Email this article to a friend

We will not keep your email address; we ask for it so your friend knows the email isn't spam.
Enter multiple addresses on separate lines or separate them with commas.
Lessons from tofacitinib in patients with cardiovascular risk factors: increased pulmonary embolism or isolated (thrombotic) pulmonary occlusion rates?
(Your Name) has forwarded a page to you from Annals of the Rheumatic Diseases
(Your Name) thought you would like to see this page from the Annals of the Rheumatic Diseases web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.